FRMD3-AS1: A Potential Drug Target and Biomarker (G102723989)

Target Name: FRMD3-AS1

NCBI ID: G102723989

FRMD3-AS1

Other Name(s): FRMD3-AS1 variant X2 | FRMD3 antisense RNA 1

FRMD3-AS1: A Potential Drug Target and Biomarker

FRMD3-AS1, a variant of the frmd3 gene that encodes a protein involved in the development and maintenance of the blood-brain barrier (BBB), has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. The blood-brain barrier is a specialized barrier that separates the brain from the surrounding blood vessels, and it plays a crucial role in maintaining the health and function of the brain. Dysfunction of the BBB has been implicated in the development of numerous neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

FRMD3-AS1 is a splicing variant of the frmd3 gene that has been identified in individuals with various psychiatric and neurological disorders. The variant has been shown to cause a reduction in the level of a protein called tight junction protein (TJP), which is involved in the formation and maintenance of the BBB. TJP is a transmembrane protein that helps to regulate the movement of cells and molecules across the BBB. It is known to play a crucial role in maintaining the integrity of the BBB, and studies have suggested that it may be involved in the development and progression of certain neurological disorders.

FRMD3-AS1 has been shown to cause a reduction in the level of TJP in the brain, which could lead to a variety of potential consequences. One of the most significant implications of reduced TJP levels is that it may contribute to the dysfunction of the BBB. The BBB is a specialized barrier that helps to protect the brain from harmful substances and disorders, and it is thought to be involved in the development of neurodegenerative diseases. Reduced TJP levels may make it more difficult for the BBB to function properly, leading to the potential for the development of neurodegenerative diseases.

In addition to its potential role in the development of neurodegenerative diseases, FRMD3-AS1 has also been shown to be involved in the development of psychiatric disorders. Studies have suggested that individuals with certain psychiatric disorders may have reduced levels of TJP, and that these reduced levels may contribute to the development and progression of these disorders. For example, individuals with major depressive disorder (MDD) have been shown to have reduced levels of TJP in the brain, and this may contribute to the dysfunction of the BBB and the development of neurodegenerative diseases.

FRMD3-AS1 has also been shown to be involved in the regulation of other proteins that are involved in the development and maintenance of the BBB. For example, studies have suggested that the protein known as E-cadherin may be involved in the formation and maintenance of the BBB, and that FRMD3-AS1 may be involved in the regulation of E-cadherin levels. E-cadherin is a transmembrane protein that is involved in cell-cell adhesion, and it is thought to play a crucial role in the formation and maintenance of the BBB.FRMD3-AS1 has been shown to regulate the levels of E-cadherin in the brain, which may contribute to the dysfunction of the BBB and the development of neurodegenerative diseases.

In conclusion, FRMD3-AS1 is a variant of the frmd3 gene that has been identified in individuals with various psychiatric and neurological disorders. The variant has been shown to cause a reduction in the level of TJP, a protein involved in the formation and maintenance of the BBB. Reduced TJP levels may contribute to the dysfunction of the BBB and the development of neurodegenerative diseases. In addition, FRMD3-AS1 has also been shown to be involved in the regulation of other proteins involved in the development and maintenance of the BBB. Further research is needed to fully understand the role of FRMD3-AS1 in the development and progression of psychiatric and neurological disorders.

Protein Name: FRMD3 Antisense RNA 1

The "FRMD3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FRMD3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets